Oral tipifarnib (60 mg/kg twice daily) suppressed tumor growth in four HRAS-mutant HNSCC PDX models relative to vehicle (n=3 per group). Six wild-type PDXs showed positive tumor-volume changes during treatment. Responses are specific to this model panel and do not establish durable tumor control. [1]
In immunocompetent mice bearing 9464D-GD2 tumors, tipifarnib plus dinutuximab reduced tumor growth and weight more than either agent alone. sEV add-back reversed tipifarnib’s single-agent effect, but the tumor-weight increase after add-back to the combination was not statistically significant (p=0.086). Other farnesylation-dependent mechanisms may contribute. [2]
HRAS-stratified HNSCC patient-derived xenograft response
Animal study · HNSCC PDX panel in athymic nude mice: four HRAS-mutant models and six HRAS-wild-type models. [1]
Four mutant PDXs showed tumor growth suppression relative to vehicle. Six wild-type PDXs showed positive tumor-volume change during treatment in the waterfall plot. The acquired main figure supports this contrast; the wild-type vehicle curves in supplemental Fig S1 were not retrieved. This short-term model panel does not establish universal HRAS dependence or durable control.
Conditions shared by the study groups
- Route
- Oral
- Frequency
- Twice daily
- Tipifarnib: HRAS-mutant PDX panel
- Model: HN1420 (A146T), HN2579 (G12S), HN2581 (G13R), HN3504 (K117N); n=3 per group
- Treatment course: Caption approximately 20 days; HN3504 followed beyond day 30 in Fig 5B.
- Reported limits: Vehicle composition and exact model-specific treatment stop times not retrieved.
- Tipifarnib: HRAS-wild-type PDX panel
- Model: HN5123, HN5111, HN5115, HN2609, HN3411, HN0626; caption describes groups of three
- Treatment course: Approximately 20 days per Fig 5A caption.
- Reported limits: No quantitative vehicle comparison adopted for wild-type PDXs; Fig S1 unavailable.
Methods and source locations
Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib
Literature results for the named compound; tested material was supplied by Kura Oncology.
Results S16; Fig 5A-B and caption; Methods in vivo mouse experiments and analysis
Tumor-volume response in four HRAS-mutant PDX models: Serial tumor-volume assessment; no exact means or percent inhibition inferred from curves. — Fig 5B and caption; Results S16
Tumor-volume change in six HRAS-wild-type PDX models during tipifarnib treatment: Waterfall plot; these bars compare before and after treatment, not a numerical treated/vehicle ratio. — Fig 5A and caption; Results S16
Tipifarnib: HRAS-mutant PDX panel · Fig 5B and caption; Results S16
Tipifarnib: HRAS-wild-type PDX panel · Fig 5A and caption; Results S16
Neuroblastoma combination treatment and sEV add-back
Animal study · Subcutaneous 9464D-GD2 neuroblastoma in immunocompetent C57BL/6J mice, 8–10 weeks old; equal male/female representation described in shared methods. [2]
Tipifarnib and dinutuximab each showed mild antitumor activity; the combination reduced tumor growth and weight more than either agent. sEV add-back reversed the single-agent tipifarnib effect, while the tumor-weight increase after add-back to the combination did not reach statistical significance (p=0.086). Additional farnesylation-dependent effects cannot be excluded.
Conditions shared by the study groups
- Treatment course
- One week after inoculation to endpoint day 24.
- Vehicle
- 20% w/v hydroxypropyl-β-cyclodextrin, pH 2.5 for oral drug/vehicle; PBS for injections.
- PBS + oral vehicle
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=7
- Route: Tail vein PBS; oral gavage vehicle
- Frequency: PBS twice weekly; oral vehicle twice daily
- Tipifarnib
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=11
- Route: Tipifarnib: oral gavage
- Frequency: Tipifarnib: twice daily
- Tipifarnib + sEVs
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
- Route: Tipifarnib: oral gavage; sEVs: tail vein
- Frequency: Tipifarnib: twice daily; sEVs: twice weekly
- Dinutuximab
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=8
- Route: Dinutuximab: tail vein
- Frequency: Dinutuximab: twice weekly
- Dinutuximab + tipifarnib
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
- Route: Tipifarnib: oral gavage; Dinutuximab: tail vein
- Frequency: Tipifarnib: twice daily; Dinutuximab: twice weekly
- Dinutuximab + tipifarnib + sEVs
- Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
- Route: Tipifarnib: oral gavage; Dinutuximab: tail vein; sEVs: tail vein
- Frequency: Tipifarnib: twice daily; Dinutuximab: twice weekly; sEVs: twice weekly
Methods and source locations
Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib
Literature results for named tipifarnib; supplier attribution is not experiment-specific.
Fig 6A-D and caption; Results s3-5; Materials and methods: Drugs and antibodies, Animal experiments, Statistical analysis
Tumor volume over time and endpoint tumor weight: Caliper tumor-volume monitoring; endpoint excised tumor weight; caption reports Student’s t-test for weights. — Fig 6B-D and caption; Results s3-5; Animal experiments
Tumor weight after sEV addition to dinutuximab plus tipifarnib: Student’s t-test as reported in Fig 6C caption; no exact weight or effect size digitized. — Fig 6C; Results s3-5, paragraph beginning To validate
PBS + oral vehicle · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments
Tipifarnib · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments
Tipifarnib + sEVs · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments
Dinutuximab · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments
Dinutuximab + tipifarnib · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments
Dinutuximab + tipifarnib + sEVs · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments